BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer
BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, announced a significant insider purchase by its Chairman and CEO, Jason Matuszewski.
On August 19, 2025, Matuszewski acquired 15,500 shares through two transactions: 2,500 shares at $6.28 and 13,000 shares at $6.51, totaling approximately $100,000. Following these purchases, his total ownership stands at 1,145,362 shares.
BioStem Technologies (OTC: BSEM), azienda MedTech specializzata in prodotti derivati dalla placenta per la cura avanzata delle ferite, ha comunicato un importante acquisto interno da parte del suo Presidente e CEO, Jason Matuszewski.
Il 19 agosto 2025 Matuszewski ha acquisito 15.500 azioni in due operazioni: 2.500 azioni a $6,28 e 13.000 azioni a $6,51, per un valore complessivo di circa $100.000. Dopo questi acquisti, la sua partecipazione totale è di 1.145.362 azioni.
BioStem Technologies (OTC: BSEM), una empresa MedTech especializada en productos derivados de la placenta para el cuidado avanzado de heridas, anunció una compra interna significativa realizada por su presidente y CEO, Jason Matuszewski.
El 19 de agosto de 2025, Matuszewski adquirió 15.500 acciones en dos transacciones: 2.500 acciones a $6,28 y 13.000 acciones a $6,51, por un total aproximado de $100,000. Tras estas compras, su propiedad total asciende a 1.145.362 acciones.
BioStem Technologies (OTC: BSEM), 상처 치료를 위한 태반 유래 제품을 전문으로 하는 메드테크 회사는 이사장 겸 CEO 제이슨 마투제프스키(Jason Matuszewski)의 내부자 주식 매입을 공지했습니다.
2025년 8월 19일, 마투제프스키는 두 건의 거래로 15,500주를 취득했습니다: 2,500주를 주당 $6.28에, 13,000주를 주당 $6.51에 매수하여 총 약 $100,000을 지불했습니다. 이 매입 후 그의 총 보유 주식은 1,145,362주입니다.
BioStem Technologies (OTC: BSEM), une société MedTech spécialisée dans les produits dérivés du placenta pour les soins avancés des plaies, a annoncé un achat d'initié important réalisé par son président et PDG, Jason Matuszewski.
Le 19 août 2025, Matuszewski a acquis 15 500 actions lors de deux transactions : 2 500 actions à $6,28 et 13 000 actions à $6,51, pour un total d'environ $100 000. Après ces achats, sa détention totale s'élève à 1 145 362 actions.
BioStem Technologies (OTC: BSEM), ein MedTech-Unternehmen, das sich auf plazentabasierte Produkte für die fortgeschrittene Wundversorgung spezialisiert hat, meldete einen bedeutenden Insiderkauf durch seinen Vorsitzenden und CEO Jason Matuszewski.
Am 19. August 2025 erwarb Matuszewski 15.500 Aktien in zwei Transaktionen: 2.500 Aktien zu $6,28 und 13.000 Aktien zu $6,51, insgesamt rund $100.000. Nach diesen Käufen beläuft sich sein Gesamtbestand auf 1.145.362 Aktien.
- CEO demonstrates confidence in company through $100,000 personal investment
- Significant insider ownership with CEO holding over 1.1 million shares
- Multiple purchase transactions showing sustained buying interest
- None.
POMPANO BEACH, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, discloses an insider purchase of common stock from Jason Matuszewski, Chairman and Chief Executive Officer of BioStem Technologies.
Mr. Matuszewski purchased a total of 15,500 shares on August 19, 2025, totaling approximately
For more information about the purchases, please visit the OTCID disclosure website HERE under Officer/Director/Affiliate Stock Transactions.
About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit biostemtechnologies.com and follow us on X and LinkedIn.
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company’s email distribution list HERE, and follow us on X and LinkedIn.
Contact BioStem Technologies, Inc.:
Website: www.biostemtechnologies.com
E-Mail: info@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342
Investor Relations:
Adam Holdsworth, BioStem Director of Investor Relations
E-Mail: adam@biostemtech.com
Phone: 917-497-9287
Or
Gilmartin Group
Philip Trip Taylor, Principal
E-Mail: philip@gilmartinir.com
Phone: 415-937-5406
FAQ
How many shares did BioStem Technologies (BSEM) CEO purchase in August 2025?
What is the total stock ownership of BioStem Technologies CEO after the recent purchase?
At what price did the BSEM CEO purchase company shares?
What does BioStem Technologies (BSEM) specialize in?
